Gilead Sciences Inc Stock Forecast for 2023 - 2025 - 2030
Updated on 04/19/2024
Gilead Sciences Inc Stock Forecast and Price Target
The average price target of $82.00 for Gilead Sciences Inc's stock set by fourteen distinguished analysts in recent weeks would represent a potential upside of approximately 23.94% from the last closing price in April, 2024 if reached by the end of the year. This potential increase is based on a high estimate of $121.00 and a low estimate of $69.00. If you're interested in GILD stock, it's important to compare it to other companies in the industry.
23.94% Upside
Gilead Sciences Inc Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Gilead Sciences Inc's Price has seen a drop from $77.00 to $0.00 – a 100.00% decrease. For the next year, analysts predict that Fair Value will reach $75.80 – an increase of 100.00%. Over the next seven years, experts believe that Gilead Sciences Inc's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$164.66 | Buy/Sell | $178.42 | 14.78% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$262.75 | Buy/Sell | $303.65 | 20.74% |
| ALXN Stock Forecast | Alexion Pharmaceuticals | - |
0
|
$182.50 | Buy/Sell | $177.38 | -100.00% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$190.52 | Buy/Sell | $299.62 | 53.26% |
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$90.07 | Buy/Sell | $111.56 | 20.68% |
Gilead Sciences Inc Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Gilead Sciences Inc's Revenue has grown by 9.83%, rising from $24.69B to $27.12B. According to 20 major analysts, Gilead Sciences Inc's Revenue will fall by 5.96% in the next year, reaching $25.50B. Professionals believe that By 2030, Gilead Sciences Inc's Revenue will fall to $26.09B– a 3.79% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| INCY Stock Forecast | Incyte | Outperform |
9
|
$52.82 | Buy/Sell | $77.05 | 46.16% |
| EXEL Stock Forecast | Exelixis | Outperform |
16
|
$22.49 | Buy/Sell | $26.44 | 20.05% |
| ARNA Stock Forecast | Arena Pharmaceuticals | - |
6
|
$99.99 | Buy/Sell | $100.00 | -100.00% |
.jpg)
Gilead Sciences Inc Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Gilead Sciences Inc's Dividend per Share has grown, moving from $2.72 to $3.00 – an increase of 10.29%. In the next year, analysts predict that Dividend per Share will jump to $3.35 – up 11.67% from the current level. Looking ahead to seven years, experts forecast that Dividend per Share will grow by 111.67%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$88.90 | Buy/Sell | $85.71 | 12.49% |
| IOVA Stock Forecast | Iovance Biotherapeutics | Buy |
4
|
$11.72 | Buy/Sell | $20.42 | 117.58% |
| ACAD Stock Forecast | ACADIA Pharmaceuticals | Outperform |
6
|
$17.07 | Buy/Sell | $33.78 | 75.75% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| FOLD Stock Forecast | Amicus Therapeutics | Outperform |
7
|
$10.33 | Buy/Sell | $17.90 | 93.61% |
| CCXI Stock Forecast | ChemoCentryx | - |
8
|
$51.99 | Buy/Sell | $52.00 | -100.00% |
| CBAY Stock Forecast | CymaBay Therapeutics | - |
8
|
$32.44 | Buy/Sell | $27.73 | -100.00% |
Gilead Sciences Inc EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Gilead Sciences Inc's EBITDA has decreased from $12.70B to $12.57B – a 1.03% drop. In the next year, analysts believe that EBITDA will reach $12.66B – an increase of 0.78%. For the next seven years, the forecast is forEBITDA to grow by 32.37%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ARWR Stock Forecast | Arrowhead Pharmaceuticals | Outperform |
7
|
$22.61 | Buy/Sell | $52.00 | 143.26% |
| VKTX Stock Forecast | Viking Therapeutics | Buy |
5
|
$64.67 | Buy/Sell | $34.00 | 77.83% |
| DRNA Stock Forecast | Dicerna Pharmaceuticals | - |
7
|
$38.01 | Buy/Sell | $35.06 | -100.00% |
Gilead Sciences Inc EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Gilead Sciences Inc's EBIT has decreased by 11.80%, going from $11.22B to $9.89B. In the coming year, analysts are expecting an increase in EBIT, predicting it will reach $11.55B – an increase of 16.78%. Over the next seven years, experts anticipate that EBIT growth for Gilead Sciences Inc will be 27.55%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CLDX Stock Forecast | Celldex Therapeutics | Buy |
11
|
$38.53 | Buy/Sell | $63.29 | 99.84% |
| VCEL Stock Forecast | Vericel | Buy |
8
|
$43.86 | Buy/Sell | $42.58 | 25.40% |
| ARDX Stock Forecast | Ardelyx | Buy |
11
|
$6.44 | Buy/Sell | $9.94 | 117.39% |
Gilead Sciences Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Gilead Sciences Inc's EPS has seen a drop from $7.09 to $0.00 – a 100.00% decrease. For the next year, analysts predict that EPS will reach $6.98 – an increase of 100.00%. Over the next seven years, experts believe that Gilead Sciences Inc's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AGIO Stock Forecast | Agios Pharmaceuticals | Outperform |
9
|
$29.43 | Buy/Sell | $40.00 | 47.81% |
| DVAX Stock Forecast | Dynavax Technologies | Outperform |
11
|
$11.34 | Buy/Sell | $25.00 | 116.05% |
| XNCR Stock Forecast | Xencor | Outperform |
6
|
$18.95 | Buy/Sell | $37.91 | 79.42% |
.jpg)